Pediatric Type 2 inflammatory diseases, including atopic dermatitis, eosinophilic esophagitis (EoE), and asthma, present significant challenges for healthcare providers due to their complex, ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved dupilumab for eosinophilic esophagitis in children in January. Patients achieved improvements ...

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce ...

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...

COVID-19 infection increases the risk for respiratory type-2 inflammatory disease and vaccination reduces the risk.

Celldex Therapeutics (NASDAQ:CLDX) slipped in premarket trading on Wednesday after releasing results from its Phase 2 study of Barzolvolimab in patients with eosinophilic esophagitis (EoE), a chronic ...

Researchers have uncovered the incidence and prevalence of the chronic allergic disorder eosinophilic esophagitis, or EoE, which can cause difficulty in swallowing as eosinophils, a type of white ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, shares the latest clinical discoveries from the BOREAS trial on type 2 inflammation in patients with chronic ...